Bio-Path Holdings
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 10
- Market Cap
- -
- Introduction
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
- Interventions
- Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05190471
- Locations
- 🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York, New York, United States
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Conditions
- Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsEndometrial CancerPeritoneal CancerSolid Tumor
- Interventions
- Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04196257
- Locations
- 🇺🇸
Holy Cross Hospital, Silver Spring, Maryland, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- Conditions
- Waldenstrom MacroglobulinemiaChronic Lymphocytic Leukemia (CLL)Follicular LymphomaMantle Cell LymphomaCutaneous T-cell Lymphoma (CTCL)Small Lymphocytic Lymphoma (SLL)Marginal Zone LymphomaPeripheral T-cell Lymphoma (PTCL)Hodgkin LymphomaDLBCL
- Interventions
- Drug: L-Bcl-2 antisense oligonucleotide
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04072458
- Locations
- 🇺🇸
Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸New York Medical College / Westchester Medical Center, Valhalla, New York, United States
🇺🇸Sarah Cannon Research Institute/Tennesee Oncology, Nashville, Tennessee, United States
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelogenous Leukemia, Ph1-Positive
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Registration Number
- NCT02923986
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: BP1001 in combination with Ventoclax plus decitabine
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02781883
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
- Prev
- 1
- 2
- Next
News
Bio-Path Holdings Reports Clinical Progress Across Cancer Pipeline with Promising Patient Responses
Bio-Path Holdings reported clinical progress across its cancer drug pipeline, with two AML patients demonstrating continued treatment durability after receiving over 15 treatment cycles and remaining in complete remission.
Bio-Path Holdings Advances Cancer Therapies with Clinical Trial Progress and $4 Million Funding
Bio-Path Holdings has secured $4 million in private placement to bolster its financial position for advancing clinical trials of its cancer treatments.
Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements
Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.
Bio-Path Holdings Expands DNAbilize Platform into Obesity and Advances Oncology Programs
Bio-Path Holdings initiated a therapeutic program, BP1001-A, for obesity and related metabolic diseases, marking the first non-cancer application of its DNAbilize® technology.
Bio-Path Holdings' BP1003 Demonstrates Therapeutic Potential in Diverse Cancers
Bio-Path Holdings announces a publication in _Biomedicines_ highlighting BP1003's therapeutic potential across various cancer types.